Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Small trial of hospitalized patients with 16 of 87 patients being treated with ivermectin, showing a significantly lower mean hospital stay with ivermectin: 7.62 vs. 13.22 days, p=0.00005. 0 of 16 ivermectin patients died vs. 2 of 71 control patients.
risk of death, 71.0% lower, RR 0.29, p = 1.00, treatment 0 of 16 (0.0%), control 2 of 71 (2.8%), NNT 36, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
hospitalization time, 42.0% lower, relative time 0.58, p < 0.001, treatment 16, control 71.
|
risk of no recovery, 71.0% lower, RR 0.29, p = 1.00, treatment 0 of 16 (0.0%), control 2 of 71 (2.8%), NNT 36, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), primary outcome.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Gorial et al., 8 Jul 2020, retrospective, Iraq, preprint, 9 authors, dosage 200μg/kg single dose.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.07.07.20145979; this version posted July 8, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC 4.0 International license .
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
(Pilot Trial)
Faiq I Gorial 1*, Sabeeh Mashhadani 2 , Hend M Sayaly 3, Basim Dhawi Dakhil 4, Marwan
M.AlMashhadani5 , Adnan M Aljabory 6 , Hassan M Abbas 7 , Mohammed Ghanim 8, Jawad I
Rasheed 9
1, 2, 6
Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
3,4,5,7,8,9
Medical City Teaching Hospital, Baghdad, Iraq
• Corresponding author email: faiqig@gmail.com
Abstract
Background: To date no effective therapy has been demonstrated for COVID-19. In vitro, studies
indicated that ivermectin (IVM) has antiviral effect.
Objectives: To assess the effectiveness of ivermectin (IVM) as add-on therapy to
hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of COVID-19.
Methods: This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate
COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose
of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine ( HCQ)and
Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in
age, gender, clinical features, and comorbidities.
The primary outcome was percentage of cured patients, defined as symptoms free to be discharged
from the hospital and 2 consecutive negative PCR test from nasopharyngeal swabs at least 24
hours apart. The secondary outcomes were time to cure in both groups and evaluated by measuring
time from admission of the patient to the hospital till discharge.
Results: Of 87 patients included in the study,t he mean age ± SD (range) of patients in the IVM
group was similar to controls [44.87 ± 10.64 (28-60) vs 45.23 ± 18.47 (8-80) years, p=0.78]
Majority of patients in both groups were male but statistically not significant [11(69%) versus 52
(73%), with male: female ratio 2.21 versus 2.7-, p=0.72)
All the patients of IVM group were cured compared with the controls [ 16 (100 %) vs 69 (97.2
%)]. Two patients died in the controls. The mean time to stay in the hospital was significantly
lower in IVM group compared with the controls (7.62 ± 2.75 versus 13.22 ±5.90 days, p=0.00005,
effect size= 0.82). No adverse events were observed
Conclusions : Add-on use of IVM to HCQ and AZT had better effectiveness, shorter hospital stay,
and relatively safe compared with controls. however, a larger prospective study with longer follow
up may be needed to validate these results.
Keywords: Ivermectin, hydroxychloroquine, azithromycin, COVID-19,
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit